Laboratory-Acquired Infections And Biosafety of High Pathogenic Risk-Group 3 Bacteria

DOI: 10.6525/TEB.202012_36(23).0001

Shu-Ying Li*, Yu-Chen Chen, Kuo-Wei Chen, Mei-Hui Liao,Hwa-Jeng Teng, Cheng-Lun Chien

2020 Vol.36 NO.23

Correspondence Author: Shu-Ying Li*

  • Center for Research, Diagnostics and Vaccine Development, Centers for Disease Control, Ministry of Health and Welfare, Taiwan

Abstract:

        With the global development of research on infectious diseases and medical microbiology, the biosafety management of the risk group 3 (RG3) bacteria in the laboratory cannot be ignored. Laboratory workers and medical practitioners should have sufficient knowledge about the most frequent laboratory infection accidents, types of exposure and transmission routes, potential biosafety risks and the preventive measures of these RG3 bacteria. This article reviewed 39 articles of the laboratory-acquired infections of RG3 bacteria reported in the literature during 1961–2019 and identified 1,347 cases. Among them, the Brucella (Brucella spp.) is the most frequent one and constituted 56.05%, followed by Francisella tularensis (21.38%) and Mycobacterium tuberculosis (17.22%). The main routes of infection include respiratory inhalation of aerosols or spores, wound or mucosal contact, needle sticks, and animal bites. Laboratory precautions include operating the RG3 pathogens in a laboratory that meets biosafety level three or higher and wearing appropriate personal protective equipment. We recommend providing vaccination or prophylactic administration and collecting blood for serological examination and follow-up of workers who may be exposed to these pathogens.